The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting iNHL.

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer ...

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm.

Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted RLTs.

Questions remain as to how FDA inspection differences between domestic and foreign drug facilities will play out.